Asia

Covance expands Singapore central lab by 50%

Monday, April 22, 2013 12:44 PM

Covance, a provider of drug development services, has completed the expansion of its central laboratory facility in Singapore to enhance the company’s current service offerings and position it to meet current and future growth of drug development in the Asia Pacific region. The expansion is the latest in Covance’s continued investment in Singapore, and an important element of the strategic investment plans for the Asia Pacific region that also includes recent growth in operations in China and Japan.

More... »


inVentiv Health forms strategic alliance with Bell Medical Solutions

Tuesday, April 16, 2013 11:58 AM

inVentiv Health, a global provider of clinical, commercial and consulting services, has formed a strategic alliance with Bell Medical Solutions, a Japanese CRO with more than 700 clinical research associates serving the growing Japanese market.

More... »


Japan establishes global fund for R&D of new medicines, vaccines, diagnostics

Wednesday, April 10, 2013 10:15 AM

Japan’s first public-private partnership to advance the development of new health technologies for the developing world The Global Health Innovative Technology Fund (GHIT Fund) has officially launched. The GHIT Fund has been established to advance the R&D of new medicines, vaccines and diagnostics to fight infectious diseases in the developing world.

More... »

GSK, A*STAR's ICES to develop new medicines for emerging markets

Wednesday, April 10, 2013 09:17 AM

GlaxoSmithKline and A*STAR's Institute of Chemical and Engineering Sciences (ICES) have signed a five-year strategic agreement to develop new evidence based formulations (EBFs) specifically for emerging markets. EBFs are medicines which are reformulated to provide additional patient benefit.

More... »

TheraVida, SK Chemicals to develop THVD-201 and THVD-202 for OAB, UUI

Wednesday, April 3, 2013 11:45 AM

TheraVida, a biopharmaceutical company based in Mountain View, Calif., and South Korea-based SK Chemicals have signed a license agreement for two of TheraVida's proprietary combination drug product candidates, THVD-201 and THVD-202. The agreement grants SK Chemicals exclusive rights to develop and commercialize THVD-201 and THVD-202 in South Korea for the treatment of overactive bladder (OAB) and urge urinary incontinence (UUI). 

More... »

AG Mednet, Biovisiq team up to bring clinical trial solutions to Asian market

Wednesday, April 3, 2013 09:49 AM

Executing its mission to bring zero-delay imaging technology to clinical trials around the world, AG Mednet has signed a Master Services Agreement with Biovisiq, a Japanese imaging core laboratory (ICL), with an aim to set the new industry standard for imaging data quality, compliance and efficiency.

More... »

Edison, Dainippon Sumitomo to develop orphan mitochondrial and adult CNS disease drugs

Friday, March 29, 2013 01:09 PM

Specialty pharmaceutical company Edison Pharmaceuticals has entered into a R&D and commercialization agreement with Dainippon Sumitomo Pharma, a Japanese pharmaceutical company, for the development of EPI-743 and EPI-589 in Japan.

More... »

ShangPharma’s shareholders approve merger agreement

Monday, March 25, 2013 10:02 AM

China-based pharmaceutical and biotechnology R&D outsourcing company ShangPharma’s shareholders have voted in favor of merger agreement in which ShangPharma Merger Sub will merge with ShangPharma, with the new entity being a wholly owned subsidiary of ShangPharma Parent.

More... »

Domain, Elite Consulting to create, invest in life science companies in China

Thursday, March 14, 2013 08:00 AM

Domain Associates, a U.S. venture capital firm investing in breakthrough life sciences technologies, and Elite Consulting, consultants and financial advisors to the Chinese pharmaceutical and medical device industry, have formed a partnership to bring the most advanced healthcare products and technologies to China. 

More... »

Marken opens pharmaceutical depot in Beijing

Monday, March 11, 2013 11:07 AM

Marken, a global clinical supply chain solutions provider, has completed its new pharmaceutical depot in Beijing, China. The new facility which provides 850 square meters of GMP compliant space for temperature controlled storage as well as distribution of clinical trial supplies is co-located with the existing Marken Beijing branch office to provide a fully integrated and best in class service to clients.

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs